

Pathogenesis and treatment of acid peptic disorders: co-inhibitors with other antiulcer agents

Clinical Therapeutics

18, 2-34

DOI: [10.1016/s0149-2918\(96\)80175-5](https://doi.org/10.1016/s0149-2918(96)80175-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 973-980.	3.7	50
2	Rabeprazole: Pharmacokinetics and Tolerability in Patients with Stable, End-Stage Renal Failure. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 927-933.	2.0	21
3	Introduction. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1-2.	3.7	6
4	Review article: the pharmacokinetics of rabeprazole in health and disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 11-17.	3.7	29
5	Review article: drug interactions with agents used to treat acid-related diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 18-26.	3.7	101
7	Review article: rabeprazole's tolerability profile in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 17-23.	3.7	11
8	Review article: rabeprazole's profile in patients with gastrointestinal diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 25-32.	3.7	4
9	Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution. <i>American Journal of Gastroenterology</i> , 1999, 94, S17-S24.	0.4	19
10	Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. <i>Digestive Diseases and Sciences</i> , 2000, 45, 845-853.	2.3	55
11	Intravenous Pantoprazole: A New Tool for Acutely Ill Patients Who Require Acid Suppression. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 11D-20D.	1.7	4
12	Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial. <i>American Journal of Gastroenterology</i> , 2000, 95, 1894-1899.	0.4	62
13	Influence of Helicobacter Pylori Eradication Therapy on 13C Aminopyrine Breath Test: Comparison Among Omeprazole-, Lansoprazole-, Or Pantoprazole-Containing Regimens. <i>American Journal of Gastroenterology</i> , 2000, 95, 2762-2767.	0.4	14
14	Rabeprazole, 20 mg Once Daily or 10 mg Twice Daily, Is Equivalent to Omeprazole, 20 mg Once Daily, in the Healing of Erosive Gastroesophageal Reflux Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2000, 35, 1245-1250.	1.5	58
15	Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 1171-1194.	1.8	9
16	Lack of Interaction between Pantoprazole and Ethanol. <i>Clinical Drug Investigation</i> , 2001, 21, 345-351.	2.2	5
17	Costs of care for irritable bowel syndrome patients in a health maintenance organization. <i>American Journal of Gastroenterology</i> , 2001, 96, 3122-3129.	0.4	174
18	Cost savings to general practice from a PPI switch. <i>British Journal of Health Care Management</i> , 2001, 7, 31-32.	0.2	2
19	Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1343-1350.	3.7	25

#	ARTICLE	IF	CITATIONS
20	Efficacy of rabeprazole once daily for acid-related disorders. <i>Digestive Diseases and Sciences</i> , 2001, 46, 587-596.	2.3	5
21	Effectiveness and Tolerability of Rabeprazole 20mg as Once-Daily Monotherapy in Treatment of Erosive or Ulcerative Gastro-Oesophageal Reflux Disease. <i>Clinical Drug Investigation</i> , 2002, 22, 279-289.	2.2	4
22	LC determination of the anti-ulcer agent CDRI-85/92 in rat serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 27, 1009-1015.	2.8	2
23	Drug Switching: The Bottom Line Isn't Always What It Seems. <i>Journal of Correctional Health Care</i> , 2004, 10, 227-237.	0.5	0
24	Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1-10.	3.7	67
25	Peptic Ulcers and Gastritis. , 2005, , 1219-1236.		0
26	Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2009-2018.	2.3	45
27	Novel effects other than antisecretory action and off-label use of proton pump inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 59-67.	1.8	19
28	Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 25, 061116055830001-???	3.7	13
29	Pharmacokinetics of the Proton Pump Inhibitor CDRI-85/92 and its Ester Prodrug, a New H ⁺ /K ⁺ -ATPase Inhibitor with Anti-ulcer Activities, after Oral Doses in Rats. <i>Arzneimittelforschung</i> , 2009, 59, 564-570.	0.4	1
30	Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor. <i>Scientia Pharmaceutica</i> , 2012, 80, 167-177.	2.0	1
31	Gastroprotective activity of <i>Cenostigma macrophyllum</i> Tul. var. <i>acuminata</i> Teles Freire leaves on experimental ulcer models. <i>Journal of Ethnopharmacology</i> , 2013, 150, 316-323.	4.1	38
32	Antiulcerogenic Compounds Isolated From Medicinal Plants. <i>Studies in Natural Products Chemistry</i> , 2016, 47, 215-234.	1.8	5
33	Proton pump inhibitors and 180-day mortality in the elderly after <i>Clostridium difficile</i> treatment. <i>Gut Pathogens</i> , 2019, 11, 29.	3.4	4
34	<i>Manilkara hexandra</i> (Roxb.) Dubard Ameliorates Acetic Acid-induced Rat Gastric Ulcer. <i>Journal of Dietary Supplements</i> , 2021, 18, 278-292.	2.6	2
35	Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1999, 16, 70.	2.2	44
36	New method for long-term monitoring of intragastric pH. <i>World Journal of Gastroenterology</i> , 2007, 13, 6410.	3.3	12
37	GERD pathogenesis, pathophysiology, and clinical manifestations.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, S4-S4.	1.3	121

#	ARTICLE	IF	CITATIONS
38	Feasibility Study on the Development of Fiber-Optic pH Sensor for Endoscope. Journal of Sensor Science and Technology, 2004, 13, 213-217.	0.2	6
39	An Open-Label, Multicenter Post Marketing Study to Assess the Symptomatic Efficacy and Safety of Troxipide [TroxiP™] in the Management of Acid Peptic Disorders in Indian Patients. British Journal of Medicine and Medical Research, 2013, 3, 1881-1892.	0.2	1
40	A Comparative Evaluation of Lafutidine and Rabeprazole in the Treatment of Gastritis and Peptic Ulcer: A Double-blind, Randomized Study in Indian Patients. British Journal of Medicine and Medical Research, 2013, 3, 1187-1198.	0.2	1
41	Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial. American Journal of Gastroenterology, 2000, 95, 1894-1899.	0.4	8
42	Costs of care for irritable bowel syndrome patients in a health maintenance organization. American Journal of Gastroenterology, 2001, 96, 3122-3129.	0.4	42
44	Potassium-competitive Acid Blocker: A Newer Target in the Treatment of Acid Peptic Disorder. SBV Journal of Basic Clinical and Applied Health Science, 2023, 6, 33-38.	0.1	0